Eli Lilly to Purchase Morphic, Green Hydrogen
Bloomberg Intelligence
Discussion on Eli Lilly's Acquisition of Morphic and Drug Pricing in the Pharmaceutical Industry
This chapter delves into Eli Lilly's $3.2 billion acquisition of Morphic, M&A trends in healthcare, discussions on drug pricing, middlemen in the pharmaceutical industry, and the importance of competition to reduce prices. The chapter also introduces Sam Fazelli, a healthcare pharma analyst, and mentions Think or Swim trading platform and CrowdStrike cybersecurity platform.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
